📖

als

active

wiki page Created: 2026-04-02T11:21:26 By: import Quality: 70% ✓ SciDEX ID: wiki-als

Related Entities

als

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

📊 Evidence Profile

Evidence Balance

+0%

Certainty

100%

Debates

Incoming

188

Outgoing

187

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Linked Artifacts (214)

mentions🧫PSP and CBS Biomarker Validation Study100%

mentions🧫N-of-1 Clinical Trial Design for CBS/PSP100%

mentions🧫Blood Biomarker vs Tau PET for Treatment Monitoring100%

mentions🧫ALS Progression Rate Heterogeneity — mechanism and biomarker100%

mentions🧫ALS Regional Onset and Spread: Network-Level Staging Model100%

mentions🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD100%

mentions🧫Environmental Exposure Causal Attribution in ALS — Experimen100%

mentions🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk100%

mentions🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study100%

mentions🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT100%

mentions🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk100%

mentions🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers100%

mentions🧫TDP-43 PET Ligand Development for FTD and ALS100%

mentions🧫Brainstem Circuit Modulation for PSP100%

mentions🧫Metabolic Pathway-Targeted Therapy in ALS100%

mentions🧫Pre-Symptomatic Detection and Intervention Timing in Genetic100%

mentions🧫Progranulin Replacement Therapy for FTD — Vector Development100%

mentions🧫s:** - Single-cell RNA-seq to measure editing efficiency acr100%

mentions🧫Sleep and Respiratory Network Interaction in ALS — Experimen100%

mentions🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des100%

mentions🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design100%

mentions🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri100%

mentions🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio100%

related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic70%

related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri70%

related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio70%

related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD70%

related🧫Brainstem Circuit Modulation for PSP70%

related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk70%

related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT70%

related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker70%

related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers70%

related🧫TDP-43 PET Ligand Development for FTD and ALS70%

related🧫PSP and CBS Biomarker Validation Study70%

related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr70%

related🧫Sleep and Respiratory Network Interaction in ALS — Experimen70%

related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des70%

related🧫Metabolic Pathway-Targeted Therapy in ALS70%

related🧫Progranulin Replacement Therapy for FTD — Vector Development70%

related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study70%

related🧫N-of-1 Clinical Trial Design for CBS/PSP70%

related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design70%

related🧫Environmental Exposure Causal Attribution in ALS — Experimen70%

related🧫ALS Regional Onset and Spread: Network-Level Staging Model70%

related🧫Blood Biomarker vs Tau PET for Treatment Monitoring70%

mentions🔬What are the mechanisms underlying rna binding protein dysre60%

mentions🔬CRISPR-based therapeutic approaches for neurodegenerative di60%

mentions🔬What are the mechanisms underlying tdp-43 phase separation t60%

mentions🔬Analyze the spectrum of microglial activation states (DAM, h60%

related🔬Analyze the spectrum of microglial activation states (DAM, h50%

related🔬What are the mechanisms underlying rna binding protein dysre50%

related🔬CRISPR-based therapeutic approaches for neurodegenerative di50%

related🔬What are the mechanisms underlying tdp-43 phase separation t50%

mentions🧫Environmental Exposure Causal Attribution in ALS — Experimen40%

related🧪Temporal Decoupling via Circadian Clock Reset40%

related🧪Mitochondrial Transfer Pathway Enhancement40%

related🧪Mitochondrial-Lysosomal Contact Site Engineering40%

related🧪Extracellular Vesicle Biogenesis Modulation40%

related🧪Epigenetic Memory Erasure via TET2 Activation40%

related🧪Glial Glycocalyx Remodeling Therapy40%

related🧪AMPK hypersensitivity in astrocytes creates enhanced mitocho40%

related🧪Metabolic Switch Targeting for A1→A2 Repolarization40%

related🧪Senescence-Induced Lipid Peroxidation Spreading40%

related🧪GFAP-Positive Reactive Astrocyte Subtype Delineation40%

related🧪Tau-Independent Microtubule Stabilization via MAP6 Enhanceme40%

related🧪Temporal TET2-Mediated Hydroxymethylation Cycling40%

related🧪Microglial Efferocytosis Enhancement via GPR32 Superagonists40%

related🧪Selective HDAC3 Inhibition with Cognitive Enhancement40%

related🧪FOXO3-Longevity Pathway Epigenetic Reprogramming40%

mentions🧫Blood Biomarker vs Tau PET for Treatment Monitoring40%

related🧪Selective Acid Sphingomyelinase Modulation Therapy40%

mentions🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio40%

related🧪GAP43-mediated tunneling nanotube stabilization enhances neu40%

related🧪Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli40%

related🧪Correcting Gut Microbial Dopamine Imbalance to Support Syste40%

related🧪Complement C1QA Spatial Gradient in Cortical Layers40%

related🧪Nucleolar Stress Response Normalization40%

related🧪Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflam40%

related🧪Microglial Purinergic Reprogramming40%

related🧪Aquaporin-4 Polarization Rescue40%

related🧪Heat Shock Protein 70 Disaggregase Amplification40%

related🧪Glymphatic System-Enhanced Antibody Clearance Reversal40%

related🧪Orexin-Microglia Modulation Therapy40%

related🧪Biorhythmic Interference via Controlled Sleep Oscillations40%

related🧪SIRT6-NAD+ Axis Enhancement Therapy40%

related🧪Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioener40%

related🧪HCN1-Mediated Resonance Frequency Stabilization Therapy40%

related🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna40%

related🧪Flotillin-1 Stabilization Compounds40%

mentions🧫TDP-43 PET Ligand Development for FTD and ALS40%

related🧪RNA-Binding Competition Therapy for TDP-43 Cross-Seeding40%

related🧪Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption40%

related🧪Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro40%

related🧪Complement C1q Mimetic Decoy Therapy40%

related🧪Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cro40%

mentions🧫Brainstem Circuit Modulation for PSP40%

related🧪Ephrin-B2/EphB4 Axis Manipulation40%

mentions🧫Pre-Symptomatic Detection and Intervention Timing in Genetic40%

mentions🧫ALS Regional Onset and Spread: Network-Level Staging Model40%

related🧪Synthetic Biology Rewiring via Orthogonal Receptors40%

related🧪Glycine-Rich Domain Competitive Inhibition40%

related🧪Lysosomal Calcium Channel Modulation Therapy40%

mentions🧫PSP and CBS Biomarker Validation Study40%

related🧪Extracellular Matrix Stiffness Modulation40%

related🧪PARP1 Inhibition Therapy40%

related🧪Pericyte Contractility Reset via Selective PDGFR-β Agonism40%

related🧪Circadian-Gated Maresin Biosynthesis Amplification40%

related🧪Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain A40%

mentions🧫s:** - Single-cell RNA-seq to measure editing efficiency acr40%

related🧪Serine/Arginine-Rich Protein Kinase Modulation40%

related🧪Proteostasis Enhancement via APOE Chaperone Targeting40%

mentions🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk40%

related🧪Purinergic P2Y12 Inverse Agonist Therapy40%

related🧪Circadian Clock-Autophagy Synchronization40%

related🧪Trans-Synaptic Adhesion Molecule Modulation40%

mentions🧫Progranulin Replacement Therapy for FTD — Vector Development40%

related🧪DNMT1-Targeting Antisense Oligonucleotide Reset40%

related🧪Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem40%

related🧪APOE-Mediated Synaptic Lipid Raft Stabilization40%

related🧪Matrix Stiffness Normalization via Targeted Lysyl Oxidase In40%

related🧪TFEB-PGC1α Mitochondrial-Lysosomal Decoupling40%

related🧪Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution40%

related🧪Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration40%

related🧪Fractalkine Axis Amplification via CX3CR1 Positive Allosteri40%

related🧪Axonal RNA Transport Reconstitution40%

related🧪VCP-Mediated Autophagy Enhancement40%

related🧪Transcriptional Autophagy-Lysosome Coupling40%

related🧪Complement C1q Subtype Switching40%

related🧪Lysosomal Membrane Repair Enhancement40%

related🧪Mitochondrial RNA Granule Rescue Pathway40%

mentions🧫Metabolic Pathway-Targeted Therapy in ALS40%

related🧪Metabolic Reprogramming via Microglial Glycolysis Inhibition40%

related🧪SASP-Mediated Complement Cascade Amplification40%

related🧪Stress Granule Phase Separation Modulators40%

related🧪Chromatin Accessibility Restoration via BRD4 Modulation40%

related🧪Mitochondrial Calcium Buffering Enhancement via MCU Modulati40%

related🧪Prefrontal sensory gating circuit restoration via PV interne40%

related🧪RAB27A-dependent extracellular vesicle engineering for mitoc40%

related🧪Arginine Methylation Enhancement Therapy40%

related🧪Lysosomal Enzyme Trafficking Correction40%

related🧪Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics40%

related🧪Liquid-Liquid Phase Separation Modifier Therapy40%

related🧪Phase-Separated Organelle Targeting40%

related🧪Age-Dependent Complement C4b Upregulation Drives Synaptic Vu40%

mentions🧫N-of-1 Clinical Trial Design for CBS/PSP40%

related🧪Quantum Coherence Disruption in Cellular Communication40%

related🧪HSP90-Tau Disaggregation Complex Enhancement40%

mentions🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD40%

related🧪Cryptic Exon Silencing Restoration40%

mentions🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers40%

mentions🧫Sleep and Respiratory Network Interaction in ALS — Experimen40%

related🧪Near-infrared light therapy stimulates COX4-dependent mitoch40%

related🧪Hypocretin-Neurogenesis Coupling Therapy40%

mentions🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri40%

related🧪Senescent Microglia Resolution via Maresins-Senolytics Combi40%

related🧪The Glial Ketone Metabolic Shunt Hypothesis40%

related🧪Netrin-1 Gradient Restoration40%

related🧪HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor40%

related🧪Astroglial Gap Junction Coordination via Connexin-43 Phospho40%

related🧪Perforant Path Presynaptic Terminal Protection Strategy40%

related🧪Glycosaminoglycan Template Disruption Approach40%

mentions🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design40%

related🧪Mitochondrial SPM Synthesis Platform Engineering40%

related🧪Synaptic Vesicle Tau Capture Inhibition40%

related🧪The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction40%

related🧪Nutrient-Sensing Epigenetic Circuit Reactivation40%

related🧪Partial Neuronal Reprogramming via Modified Yamanaka Cocktai40%

related🧪Oligodendrocyte White Matter Vulnerability40%

related🧪Circadian Rhythm Entrainment of Reactive Astrocytes40%

related🧪RNA Granule Nucleation Site Modulation40%

related🧪R-Loop Resolution Enhancement Therapy40%

related🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro40%

related🧪Excitatory Neuron Vulnerability via SLC17A7 Downregulation40%

related🧪KDM6A-Mediated H3K27me3 Rejuvenation40%

related🧪Sphingolipid Metabolism Reprogramming40%

related🧪Gamma entrainment therapy to restore hippocampal-cortical sy40%

related🧪TET2-Mediated Demethylation Rejuvenation Therapy40%

mentions🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT40%

related🧪Cross-Seeding Prevention Strategy40%

related🧪Reelin-Mediated Cytoskeletal Stabilization Protocol40%

related🧪Circadian Glymphatic Rescue Therapy (Melatonin-focused)40%

related🧪Magnetosonic-Triggered Transferrin Receptor Clustering40%

related🧪LRP1-Dependent Tau Uptake Disruption40%

mentions🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des40%

related🧪Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy40%

related🧪Osmotic Gradient Restoration via Selective AQP1 Enhancement 40%

related🧪Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modu40%

related🧪Astrocyte-Mediated Neuronal Epigenetic Rescue40%

related🧪Noradrenergic-Tau Propagation Blockade40%

related🧪Low Complexity Domain Cross-Linking Inhibition40%

related🧪CX43 hemichannel engineering enables size-selective mitochon40%

related🧪Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th40%

mentions🧫ALS Progression Rate Heterogeneity — mechanism and biomarker40%

related🧪Optogenetic Microglial Deactivation via Engineered Inhibitor40%

related🧪HDAC3-Selective Inhibition for Clock Reset40%

related🧪Palmitoylation-Targeted BACE1 Trafficking Disruptors40%

related🧪Metabolic Circuit Breaker via Lipid Droplet Modulation40%

related🧪Sleep Spindle-Synaptic Plasticity Enhancement40%

related🧪CYP46A1 Overexpression Gene Therapy40%

related🧪Transglutaminase-2 Cross-Linking Inhibition Strategy40%

related🧪Lysosomal Positioning Dynamics Modulation40%

related🧪TFAM overexpression creates mitochondrial donor-recipient gr40%

related🧪Complement-Mediated Synaptic Pruning Dysregulation40%

related🧪SASP-Driven Aquaporin-4 Dysregulation40%

related🧪Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulat40%

related🧪Autophagosome Maturation Checkpoint Control40%

related🧪Targeted Butyrate Supplementation for Microglial Phenotype M40%

mentions🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study40%

related🧪Blood-Brain Barrier SPM Shuttle System40%

related🧪Astrocytic Connexin-43 Upregulation Enhances Neuroprotective40%

related🧪Adenosine-Astrocyte Metabolic Reset40%

related🧪SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK40%

related🧪Gap Junction Hemichannel Modulation for Controlled Mitochond40%

related🧪Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu40%

als

💬 Discussion